FDCA busts anxiety drug production racket

Ahmedabad:  The state Food and Drugs Control Administration (FDCA) on Thursday busted a racket involved in the illegal production and sale of bulk drug pregabalin across Ahmedabad and Ankleshwar. Pregabalin is a key active pharmaceutical ingredient (API) used in medications to treat neuropathic pain, epilepsy and generalised anxiety disorder.

The crackdown revealed that Estime Enterprise in Ahmedabad was trading the API without a valid licence. Evidence found at their premises indicated the sales of approximately 4,300kg of pregabalin worth around Rs 85 lakh. The investigation led authorities to Axis Pharmachem in Ankleshwar and Iconic Pharmachem in Panoli.

“Iconic Pharmachem was reportedly caught producing pregabalin in their chemical factory despite lacking the necessary drug manufacturing licence, while Axis Pharmachem was sealed for allegedly using its licence to facilitate sales from Iconic Pharmachem for a commission, without generating proper documents,” said FDCA commissioner H G Koshia.

“Nearly 1,000kg worth Rs 21.50 lakh was seized from Iconic Pharmachem in Panoli. A branch of Estime Enterprise in Bharuch was found to be selling pregabalin and other API chemicals without licences and generating their own test reports. From here, 35kg of pregabalin was seized,” Koshia said.

Individuals allegedly involved in this extensive scheme include Nimesh Shah and Harish Ashwin Joshi from Estime Enterprise, Pravin Patel from Axis Pharmachem, Bhavesh Chalodiya from Iconic Pharmachem and Lalit Raiyani from Biocrom Analytical Lab. The analytical lab, which operated without the required licence or legal documents, was found to have been providing test reports via WhatsApp.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit